Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

11-12 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
29/09/26	SEK 0.4140	-0.60%	1,013,001
28/09/26	SEK 0.4165	-0.83%	1,568,268
25/09/26	SEK 0.4200	+1.33%	1,951,460
24/09/26	SEK 0.4145	-2.81%	805,079
23/09/26	SEK 0.4265	+6.09%	1,486,835

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 17:00:00 29/09/2026 BST			5-day change	1st Jan Change
0.4140 ^SEK	-0.60%		-3.72%	-50.06%

09-24	Alzinova's Phase II Study to Be Presented at Alzheimer's Conference	FW
09-21	Alzinova Initiates Global Phase Ii Start-Up of Therapeutic Vaccine Alz-101 and Advances Blood-Based Diagnostic Program	CI

Market Cap	83.89M 8.4M 7.41M 7M 6.35M 11.93M 807M 12.02M 32.33M 412M 31.57M 30.88M 1.33B	P/E 2026 *	-1.53x	P/E 2027 *	-1.09x
Enterprise Value	67.89M 6.8M 5.99M 5.67M 5.14M 9.65M 653M 9.73M 26.16M 333M 25.55M 24.99M 1.08B	EV / Sales 2026 *	2.17x	EV / Sales 2027 *	-
Free-Float	46.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Börse Stuttgart	78D	Delayed
Deutsche Boerse AG	78D	Delayed
CBOE		Real-time
CBOE		Real-time

09-24	Alzinova's Phase II Study to Be Presented at Alzheimer's Conference	FW
09-21	Alzinova Initiates Global Phase Ii Start-Up of Therapeutic Vaccine Alz-101 and Advances Blood-Based Diagnostic Program	CI
09-11	Stockholm stocks ended Friday higher	FW
09-11	Calendar Monday September 14 - Friday September 18	FW
09-11	Alzinova: Redeye cuts justified value to SEK 0.90	FW
09-11	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
09-11	Asker plunges on choppy Stockholm market	FW
09-11	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
09-11	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
09-11	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT
09-10	Alzinova AB Initiates Operational Start-Up Of Global Phase 2 Study With ALZ-101	CI
08-20	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

09-24	Alzinova’s Phase II study with ALZ-101 accepted for presentation at international Alzheimer’s conference	AQ
09-22	The subscription period in Alzinovas rights issue of units starts today	AQ
09-21	Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need	GL
09-18	Alzinova publishes information memorandum in connection with rights issue of units	AQ
09-11	Alzinova: Phase II study update and SEK51 rights issue	AQ

1 day	-0.60%
1 week	-3.72%
Current month	-48.25%
1 month	-50.71%
3 months	-24.04%
6 months	-29.59%
Current year	-50.06%

1 week	0.4	0.43
1 month	0.4	1.04
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	30/09/2024
Anders Sandberg COO	Chief Operating Officer	54	16/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	26/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	31/08/2015
Anders Waas BRD	Director/Board Member	69	31/12/2017
Carol Routledge BRD	Director/Board Member	-	31/12/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-0.60%	-3.72%	-65.50%	-85.57%	8.48M
LONZA GROUP AG	-0.03%	+6.41%	+11.83%	+38.36%	49.06B
IQVIA HOLDINGS INC.	-0.73%	-0.33%	+49.81%	+36.06%	44.6B
REVOLUTION MEDICINES, INC.	+1.36%	+6.08%	+365.57%	+624.08%	43.24B
BEONE MEDICINES AG	-0.47%	-0.04%	+12.10%	+98.46%	41.73B
CELLTRION, INC.	+0.34%	-1.38%	+5.53%	+47.36%	29.93B
MEDPACE HOLDINGS, INC.	+1.00%	-0.33%	+25.23%	+152.51%	17.19B
TEMPUS AI, INC.	-2.94%	+5.83%	+5.22%	-	15.35B
EUROFINS SCIENTIFIC SE	-3.20%	-2.38%	+25.00%	+43.67%	15.54B
ASCENDIS PHARMA A/S	-0.86%	-4.01%	-	-	15.11B
Average	-0.61%	+1.83%	+48.31%	+119.37%	27.18B
Weighted average by Cap.	-0.27%	+2.42%	+78.63%	+162.87%

	2026 *	2027 *
Net sales	31.35M 3.14M 2.77M 2.62M 2.37M 4.46M 302M 4.49M 12.08M 154M 11.8M 11.54M 497M	-
Net income	-4.45M -446K -393K -371K -337K -633K -42.8M -637K -1.71M -21.84M -1.67M -1.64M -70.6M	-77M -7.71M -6.8M -6.43M -5.83M -10.95M -741M -11.03M -29.67M -378M -28.98M -28.34M -1.22B
Net Debt	-16M -1.6M -1.41M -1.34M -1.21M -2.27M -154M -2.29M -6.17M -78.54M -6.02M -5.89M -254M	-19M -1.9M -1.68M -1.59M -1.44M -2.7M -183M -2.72M -7.32M -93.27M -7.15M -6.99M -301M